196 related articles for article (PubMed ID: 38939189)
21. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
22. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
23. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
[TBL] [Abstract][Full Text] [Related]
24. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses.
Kirtipal N; Bharadwaj S; Kang SG
Infect Genet Evol; 2020 Nov; 85():104502. PubMed ID: 32798769
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
26. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.
Alam MS
Heliyon; 2023 Feb; 9(2):e13285. PubMed ID: 36744070
[TBL] [Abstract][Full Text] [Related]
27. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
[TBL] [Abstract][Full Text] [Related]
28. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
29. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic.
Chadha J; Khullar L; Mittal N
Environ Microbiol; 2022 Jun; 24(6):2615-2629. PubMed ID: 34320263
[TBL] [Abstract][Full Text] [Related]
30. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
31. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
32. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
33. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants.
Ghimire D; Han Y; Lu M
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746726
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19.
Chatterjee SK; Saha S; Munoz MNM
Front Mol Biosci; 2020; 7():196. PubMed ID: 32850977
[TBL] [Abstract][Full Text] [Related]
35. Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.
Nayak B; Lal G; Kumar S; Das CJ; Saraya A; Shalimar
Front Cell Infect Microbiol; 2021; 11():753249. PubMed ID: 34760721
[TBL] [Abstract][Full Text] [Related]
36. How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?
Noor R
Bull Natl Res Cent; 2022; 46(1):255. PubMed ID: 36254244
[TBL] [Abstract][Full Text] [Related]
37. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.
Tulimilli SV; Dallavalasa S; Basavaraju CG; Kumar Rao V; Chikkahonnaiah P; Madhunapantula SV; Veeranna RP
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298616
[TBL] [Abstract][Full Text] [Related]
38. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.
Totura AL; Whitmore A; Agnihothram S; Schäfer A; Katze MG; Heise MT; Baric RS
mBio; 2015 May; 6(3):e00638-15. PubMed ID: 26015500
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
Noor R; Shareen S; Billah M
Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
